Bipolar II Disorder Clinical Trial
Official title:
An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
The primary goal of this study is to examine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder (BD II). Fourteen participants, ages 18 to 70 with clinically diagnosed BD II with active depression, in active outpatient mental health treatment, and who meet all other inclusion and exclusion criteria at screening will be enrolled. After baseline assessments, participants will engage in preparatory visits with trained facilitators, followed by an initial drug administration of oral psilocybin,supervised by the facilitators and a clinician who will conduct safety monitoring throughout. Participants will complete assessment and integration sessions with the facilitators subsequently in order to help process the experience. Participants who tolerated the first dosage may be asked to complete a second psilocybin dosing session, involving the same preparation, procedures, integration, and supervision as the first. Primary outcome measures will assess safety, tolerability, and feasibility of study procedures. Efficacy will be measured by change in depression as measured by the MADRS three weeks after the final psilocybin administration. Exploratory outcome measures will assess changes in sleep, quality of life, and therapeutic engagement. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
| Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
| Completed |
NCT00761761 -
Sensoril(Ashwaganhda)for Bipolar Disorder
|
Phase 3 | |
| Active, not recruiting |
NCT04561622 -
Emotional Proactive Processing in Bipolar Disorder
|
||
| Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
| Recruiting |
NCT06184581 -
Lithium Versus Lamotrigine in Bipolar Disorder, Type II
|
Phase 4 | |
| Active, not recruiting |
NCT03484494 -
Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression
|
N/A | |
| Recruiting |
NCT05400785 -
Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning
|
N/A | |
| Completed |
NCT05340504 -
Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder
|
Phase 2 | |
| Active, not recruiting |
NCT05249309 -
Naturalistic Study of Ketamine in the Treatment of Depression
|
||
| Recruiting |
NCT04211428 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
|
||
| Completed |
NCT03822416 -
Treating Smokers With Mental Illness
|
Phase 2 | |
| Completed |
NCT01588457 -
Sequential Multiple Assignment Treatment for Bipolar Disorder
|
Phase 4 | |
| Completed |
NCT03156504 -
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
|
Phase 4 | |
| Recruiting |
NCT05004896 -
Ketamine for Treatment-Resistant Bipolar Disorder
|
Phase 2 | |
| Terminated |
NCT02491307 -
Ginger.io Behavioral Health Study
|
N/A | |
| Recruiting |
NCT05427123 -
Children's Bipolar Network Treatment Trial I
|
||
| Not yet recruiting |
NCT05705063 -
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness
|
N/A | |
| Completed |
NCT02593643 -
Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.
|
Early Phase 1 |